RecruitingMigraine
Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies
Eligible age
18–65 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Being able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine.
Sponsor: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
You may qualify if…
- ✓ Patients aged between 18 and 65 years.
- ✓ Caucasian ethnicity.
- ✓ Patients diagnosed with migraine with and without high-frequency episodic aura (more than 8 days of migraine per month) or chronic by a neurologist expert in headaches and according to the criteria proposed in the International Classification of Headache Diseases, 3rd edition (ICHD- 3).
- ✓ Have at least one year of history of migraine.
- ✓ Patients must maintain stable preventive treatment in the previous month and not have received botulinum toxin in the month prior to starting the monoclonal antibody.
- ✓ Patients able to describe their clinical situation and the characteristics of their headache.
- ✓ Grant your informed consent.
You may not qualify if…
- ✕ Patients who present with another type of non-migraine headache, with the exception of headache due to excessive use of analgesic medication.
- ✕ Neurological focus in the examination.
- ✕ Pregnancy or breastfeeding period.
- ✕ Patients with cognitive deficiency or pathology that may prevent or hinder the correct completion of the study.
- ✕ Patients who require changes in preventive treatment during the first 6 months after starting treatment with monoclonal antibodies.
- ✕ Patients who present any significant adverse effect that requires withdrawal or change of anti-CGRP drug.
Source: ClinicalTrials.gov · NCT06459648 · last updated 2025-09-24